Clinical evaluation of ceftriaxone

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Acute bacterial infections pose significant health challenges.
• Effective antibiotic therapy is crucial for patient outcomes.
• Ceftriaxone is a third-generation cephalosporin with broad-spectrum activity.

Purpose of the Study:

• To evaluate the efficacy and safety of ceftriaxone in treating acute bacterial infections.
• To assess the clinical response and microbiological eradication rates.
• To determine ceftriaxone's pharmacokinetic profile in infected patients.

Main Methods:

• Seventy-seven patients with acute bacterial infections received intravenous ceftriaxone (1 gm every 12 hours).
• Efficacy was evaluated in 58 patients across various infection types (respiratory, urinary, soft tissue).
• Pathogen eradication, clinical response, and adverse effects were monitored.

Main Results:

• A satisfactory clinical response was observed in 93% of infections.
• Bacteriological eradication occurred in 94% of pretherapy pathogens, including common culprits like H. influenzae and S. pneumoniae.
• Ceftriaxone achieved therapeutic levels in cerebrospinal fluid and abscess fluid.
• Adverse effects were mild, with diarrhea (4%) and elevated transaminase levels (10%) being most common.

Conclusions:

• Ceftriaxone is a highly effective and well-tolerated treatment for acute bacterial infections.
• The antibiotic demonstrated broad efficacy against a range of pathogens.
• Therapeutic drug levels were achieved in key infection sites, supporting its clinical utility.